Evidence map›Paper›PMID 33549144›Full record

ArticleMicrobiome2021

Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models.

Francesco Strati, Meritxell Pujolassos, Claudia Burrello, Maria Rita Giuffrè, Georgia Lattanzi, Flavio Caprioli, Jacopo Troisi, Federica Facciotti

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Microbiome, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 121 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Microbiology spectrum · 2026
    Article
  6. Effects and mechanism ofWorld journal of gastroenterology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Microbiology spectrum · 2025
    Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Francesco StratiDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. francesco.strati@ieo.it.ORCID 0000-0001-7217-3355
Meritxell PujolassosTheoreo srl, Spin-off Company of the University of Salerno, Montecorvino Pugliano, Italy.
Claudia BurrelloDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Maria Rita GiuffrèDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Georgia LattanziDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Flavio CaprioliDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Jacopo Troisi *Theoreo srl, Spin-off Company of the University of Salerno, Montecorvino Pugliano, Italy.
Federica Facciotti *Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. federica.facciotti@ieo.it.
European Institute of Oncology · ITUniversity of Salerno · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe gut microbiota plays a central role in host physiology and in several pathological mechanisms in humans. Antibiotics compromise the composition and functions of the gut microbiota inducing long-lasting detrimental effects on the host. Recent studies suggest that the efficacy of different clinical therapies depends on the action of the gut microbiota. Here, we investigated how different antibiotic treatments affect the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in an experimental colitis model and in ex vivo experiments with human intestinal biopsies.

resultsMurine fecal donors were pre-treated with different antibiotics, i.e., vancomycin, streptomycin, and metronidazole before FMT administration to colitic animals. The analysis of the gut microbiome, fecal metabolome, and the immunophenotyping of colonic lamina propria immune cells revealed that antibiotic pre-treatment significantly influences the capability of the microbiota to control intestinal inflammation. Streptomycin and vancomycin-treated microbiota failed to control intestinal inflammation and were characterized by the blooming of pathobionts previously associated with IBD as well as with metabolites related to the presence of oxidative stress and metabolism of simple sugars. On the contrary, the metronidazole-treated microbiota retained its ability to control inflammation co-occurring with the enrichment of Lactobacillus and of innate immune responses involving iNKT cells. Furthermore, ex vivo cultures of human intestinal lamina propria mononuclear cells and iNKT cell clones from IBD patients with vancomycin pre-treated sterile fecal water showed a Th1/Th17 skewing in CD4

conclusionsDiverse antibiotic regimens affect the ability of the gut microbiota to control intestinal inflammation in experimental colitis by altering the microbial community structure and microbiota-derived metabolites. Video Abstract.

Indexed as

Disease Models, AnimalFecal Microbiota TransplantationAnimalsAnti-Bacterial AgentsColitisDysbiosisFemaleGastrointestinal MicrobiomeHumansMaleMetronidazoleMiceNatural Killer T-CellsStreptomycinTh17 CellsTh1 CellsAnti-Bacterial AgentsMetronidazoleStreptomycinVancomycinAntibioticsFMTGut microbiotaIBDiNKT

Identifiers

PMID33549144
PMCPMC7868014
OpenAlexW3127310493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.